US 9,717,723 B2  Page 3  (56)  References Cited  OTHER PUBLICATIONS  Author Unknown, "From Antinutrient to Phytonutrient: phytic acid  gains respect." HighBeam Research, Environmental Nutrition, Apr.  1, 2004, 2 printed pages. URL: http://www.highbeam.com/doc/  lGl-116341390.htrnl/print (accessed Nov. 4, 2011).  Bobo et al., "Convection-enhanced delivery of macromolecules in  the brain",  PNAS  91:2076-2080, 1994.  Boman et al.,  "Optimization of the retention properties of  vincristine in liposomal system",  Biochimica et Biophysica Acta,  1152:253-258 (1993).  CAS Registry Record for 23214-92-8 (doxorubicin), entered STN  Nov. 16, 1984.  CAS Registry Record for 97682-44-5 (irinotecan), entered STN  Aug. 18, 1985.  Chou et al., "Effect of Composition on the Stability of Liposomal  Irinotecan Prepared by a pH Gradient Method",  J Bioscience and  Bioengineering,  95(4):405-408, 2003.  Colbern et al., "Encapsulation of the Topoisomerase I Inhibitor  GL147211C in Pegylated (STEALTH) Liposomes: Pharrnacokinet› ics and Antitumor Activity in HT29 Colon Tumor Xenografts",  Clin. Cancer Research  4:3077-3082, 1998.  Dickinson et al., "Canine model of convection-enhanced delivery of  liposomes containing CPT-11 monitored with real-time magnetic  resonance imaging",  J Neurosurg  108:989-998, 2008.  Dickinson et al., "Canine spontaneous glioma: A translational model  system  for  convection-enhanced  delivery",  Neuro-Oncology  10:1093, 1-13, 2010.  Drummond et al., "Development of a Highly Active Nanoliposomal  Irinotecan Using a Novel Intraliposomal Stabilization Strategy",  Cancer Res  66(6):3271-3277, 2006.  Emerson et al.,  "Antitumor Efficacy,  Pharrnacokinetics, and  Biodistribution of NX 211: A Low-Clearance Liposomal Formula› tion of Lurtotecan",  Clinical Cancer Research  6:2903 2912,2000.  Grahn  et  al.,  "Non-PEGylated liposomes  for  convection› enhanced ... experience",  J Neurooncol  95: 185-197, 2009.  Haran et al., "Transmembrane ammonium sulfate gradients in  lipsomes produce efficient and stable entrapment of amphipathic  weak bases",  Biochimica et Biophysica Acta,  1151-201-215, 1993  Hattori et al., "Novel irinotecan-loaded liposome using phytic acid  with high therapeutic efficacy for colon tumors",  J of Controlled  Release  136:30-37, 2009.  Hong et al. "Anti-HER2 Immunoliposomes for Targeted Drug  Delivery, Annals of the New York Academy of Sciences." vol. 886,  pp. 293-296. Dec. 1999.  Katsu et al., "Ion-Selective Electrode for Transmembrane pH Dif› ference Measurements",  Anal. Chem.  73:1849-1854, 2001.  Kirpotin  et  al.,  "Sterically  Stabilized  Anti-HER2  Immunoliposomes: Design and Targeting to Human Breast Cancer  Cells in Vitro", Biochemist 36:66-75, 1997.  Ko et al., "A Multinational Phase II Study of PEP02 (MM-398),  Liposome Irinotecan, for Patients with Gemcitabine-refractory  Metastatic Pancreatic Cancer,"  Suppl. Abstract  4069. (2011).  Krauze et al., Convection-enhanced delivery of nanoliposomal  CPT-11 (irinotecan) and PEGylated liposornal doxorubicin ( doxil)  in rodent intracranial brain tumor xenografts,  Neuro-Oncology,  pp.  393-403, Oct. 2007.  Lee et al. "Novel Chondroitin Sulfate binding Cationic Liposomes  Loaded with Cisplatin Efficiently Suppress the Local Growth and  Liver Metastasis of Tumor Cells in Vivo,"  Cancer Research  62,  Aug. 1, 2002, 4282-4288.  Liu et al., "A Versatile Prodrug Approach for Liposomal Core› Loading of Water-Insoluble Camptothecin Anticancer Drugs",  J  Am. Chem. Soc.  124:7650-7651, 2002.  Maddison et al. "Small Animal Clinical Pharmacology." 2002. p.  474.  Mamot et al., "Extensive distribution of liposomes in rodent brains  and brain tumors following convection-enhanced delivery",  J  Neuro-Oncology  68:1-9, 2004.  Maurer-Spurej et al., "Factors influencing uptake and retention of  amino-containing drugs in large unilamellar vesicles exhibiting  transmembrane pH gradients",  Biochemica at Biophysica Acta  1416: 1-10, 1999.  Mayer et al.,  Cancer Research  49:5922-5930, 1989.  Messerer et al., "Liposomal Irinotecan: Formulation Development  and Therapeutic Assessment in Murine Xenograft Models of  Colorectal Cancer",  Clinical Cancer Research  10:6638-6649 2004.  Miles et al. "Combination Versus Sequential Single-Agent Therapy  in Metastatic Breast Cancer,"  The Oncologist,  ?(suppl 6), 2002, pp.  13-19.  Morrison et al., "Focal delivery during direct infusion to brain: role  of flow rate, catheter diameter, and tissue mechanics",  Am. J  Physiol. Regulatory Integrative Comp. Physiol.  277:1218-1229  1999.  Morrison et al., High-flow Microinfusion: Tissue Penetration and  Pharmacodynamics,  Am. J Physiol.,  266:R292-R305,1994.  Nentwich, PF. "Intravenous Therapy." 1990. p. 310.  Neve et al., "Biological Effects of Anti-ErbB2 Single Chain Anti› bodies Selected for Internalizing Function",  Biochemical and Bio› physical Research Communications,  280:274-279 (2001).  Nielsen  et  al.,  "Therapeutic  efficacy  of  anti-ErbB2  immunoliposomes targeted by a phage antibody selected for cellular  endocytosis",  Biochimica et Biophysica Acta,  1591: 109-118 (2002).  Noble et al., "Novel Nanoliposomal CPT-11 Infused by Convection› Enhanced Delivery in Intracranial Tumors: Pharmacology and Effi› cacy",  Cancer Res.,  66(5):2801-2806, 2006.  Ochi et al., "Crystalline Salts of Sucrose Octasulfate",  Pharmaceu› tical Society of Japan  28:638-641, 1980.  PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into  a Licensing and Collaboration Agreement on PEPO2 (MM-398),  Nanoliposomal Irinotecan, Press Release May 9, 2011.  Pharmaengine,  www.pharmaengine.com/pep02.htrnl  Webpage  titled "PEP02". Aug. 4, 2011.  Poul et al., "Selection of Tumor-Specific Internalizing Human  Antibodies from Phage Libraries",  J Mo!. Biol.,  301:1149-1161  (2000).  Ramsay et al., "A Novel liposomal irinotecan formulation with  significant  to improve drug retention",  European J  of  Pharmaceutics and Biopharmaceutics  68:607-617, 2008.  Sadzuka et al. "Effect of Liposomalization on the Antitumor Activ› ity, Side-Effects, and Tissue Distribution ofCPT-11," Cancer Letters  127 (1998) 99-106.  Saito et al., "Convection-enhanced delivery of Ls-TPT enables an  effective, continuous, low-dose chemotherapy against malignant  glioma xenograft model",  Neuro-Oncology,  pp. 205-214 2006.  Saito et al., "Distribution of Liposomes into Brain and Rat Brain  Tumor Models by Convection-Enhanced Delivery Monitored with  Magnetic Resonance Imaging",  Cancer Research  64:2572-2579  2004.  Saito et al., Tissue affinity of the infusate affects the distribution  volume during convection-enhanced delivery into rodent brans:  Implications for local drug delivery,  J Neuroscience Methods  154:225-232, 2006.  Shimada et al. "Irinotecan Plus Low-Dose Cisplatin for Alpha  Fetoprotein-Producing Gastric Carcinoma with Multiple Liver  Metastases: Report of Two Cases,"  Surg Today  (2002) 32:1075  1080.  Tardi et al., Liposomal Encapsulation ofTopotecan Enhances Anti› cancer Efficacy in Murine and Human Xeno raft Models,  Cancer  Research  60:3389-3393, 2000.  Werbel et al., "Basically Substituted Ellipticine Analogues as Poten› tial Antitumor Agents",  J Med. Chem.  29:1321-1322, 1986.  Yamashita  et  al.,  "Convection-enhanced  delivery  of  a  topoisomerase  I  inhibitor  (nanoliposomal  topotecan)  and  topoisomerase II inhibitor (pegylated liposomal doxorubicin) in  intracranial brain tumor xeno rafts"  Neuro-Oncology  8:1-9 2006.  Yeh et al. "Structural Basis for Activation of Fibroblast Growth  Factor Signaling by Sucrose Octasulfate,"  Molecular and Cellular  Biology,  vol. 22 No. 20, Oct. 2002, pp. 7184-7192.  Zhu et al.,  Cancer Chemotherapy  &  Pharmacology,  39:138-142  1996. 